Dihexa
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Dihexa is an experimental cognitive-repair compound aimed at structural synaptogenesis over weeks, not acute stimulation; the plausible lane is neurological deficit or injury recovery, not healthy productivity chasing.
Specialist-only risk posture: systemic HGF/c-Met amplification creates a theoretical oncogenic concern, human trials are absent, and the foundational 2013 PNAS paper carries a Notice of Concern.
Dihexa is an experimental cognitive-repair compound aimed at structural synaptogenesis over weeks, not acute stimulation; the plausible lane is neurological deficit or injury recovery, not healthy productivity chasing.
Main watchpoints are theoretical oncogenic risk via systemic HGF/c-Met amplification, zero human clinical trials, reduced confidence from the 2013 PNAS Notice of Concern, and FDA Category 2 removal in April 2026.
The unusual appeal is oral, BBB-permeable access to structural synaptogenesis; that value is highest when there is a real cognitive deficit and weakest for healthy nootropic optimization.
Highly variable and population-dependent; clearest community evidence is in neurological injury and deficit populations; weakest in healthy cognitive optimizers; product-identity fraud inflates null-effect reports
Intro
Dihexa (PNB-0408; N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic hexapeptide derived from angiotensin IV, developed at Washington State University by McCoy et al.
Its primary mechanism is HGF stabilization: Dihexa binds to and protects hepatocyte growth factor (HGF) from enzymatic degradation, which amplifies HGF/c-Met receptor signaling. Enhanced c-Met activation activates the PI3K/AKT pathway and drives synaptogenesis — the physical formation of new synaptic connections between neurons. A secondary mechanism involves AT4 receptor agonism and IRAP (insulin-regulated aminopeptidase) inhibition, which prolongs neuropeptide half-lives at the synapse and improves memory consolidation. Dihexa is orally bioavailable and blood-brain barrier permeable — a key pharmacological advantage over exogenous BDNF (MW ~27 kDa) and other neurotrophins that cannot cross the BBB and are rapidly degraded by DPP-4 enzymes. The compound operates via a genomic/structural mechanism with long-latency effects: structural synaptic architecture changes emerge over weeks, not acutely. The foundational McCoy et al. (2013) PNAS paper demonstrated dose-dependent reversal of Alzheimer's-like deficits in rodent models; a 2021 Horobets paper provided limited independent replication. No human randomized controlled trials have been conducted. The McCoy 2013 paper carries a Notice of Concern (not retracted, but scientific confidence is reduced). FDA removed Dihexa from Category 2 in April 2026, narrowing regulated compounding pathways. The '10 million times more potent than BDNF' marketing claim refers to molar effective concentration in cell culture (picomolar vs nanomolar) — not real-world cognitive effect magnitude; this framing has driven unrealistic expectations in the community.
Observed Effects
The most consistently reported subjective effects are improved memory consolidation and enhanced focus with a qualitative character distinct from stimulants — no jitteriness, no crash, no acute 'felt' onset.
Effects emerge over weeks of use, consistent with the structural synaptogenesis mechanism. Practitioners describe Dihexa as enabling neurons to 'communicate with each other' — a prerequisite for all downstream plasticity gains — positioning it as the architectural layer in nootropic stacks. A second practitioner framing is 'genomic player': take it not to feel better today but to be better weeks from now. Improved learning rate during active cognitive engagement is reported; passive administration without deliberate mental challenge yields limited benefit. Persistence after discontinuation is reported by community members and paralleled in indirect class evidence — practitioners in the neuroplasticity compound class (Semax, Selank, Cerebrolysin) report structural effects persisting 4+ months after stopping. In neurological injury populations (TBI, post-concussion, anoxic brain injury), the most compelling case reports exist, including the Anita Welch concussion recovery narrative. In the healthy biohacker population, effects are most contested: uncertain subjective benefit against an uncertain oncogenic risk creates a risk-benefit calculus that has driven high discontinuation rates. The 'dumb life fatigue' motivational driver — cognitive restoration rather than optimization — characterizes most adopters. Null reports are substantially inflated by documented product-identity fraud; HPLC confirmation has shown zero-active-product Dihexa in circulation.
Field Reports
The strongest community recovery narratives come from neurological injury populations: Anita Welch documented meaningful cognitive recovery after post-concussion use; a pediatric anoxic brain injury case exists in community record representing compassionate use in a severe neurological context. Community practitioners report that the neuroplasticity compound class (including Semax, Selank, Cerebrolysin as Dihexa's structural siblings) produces durable effects — one practitioner reports neurogenic effects 'still there' 4+ months after stopping, suggesting structural synaptic changes may persist after discontinuation. Negative or null outcomes dominate overall community reporting: one autism-spectrum user discontinued after 1 year because benefit remained uncertain and cancer concern persisted; another user discontinued after weeks for the same efficacy-versus-oncology asymmetry; aggregate nootropic-community tone is cautious; the early adopter who documented skin mole growth discontinued over oncogenic concern. The dominant discontinuation driver is not felt side effects but the asymmetry of uncertain upside versus potentially irreversible oncogenic downside. HPLC-confirmed zero-active-product Dihexa means some null reports may reflect zero-active-product exposure rather than biological nonresponse. Practical observations from community logs: GI distress is manageable with food co-administration; the compound requires active cognitive engagement to yield benefit (users who administered passively without deliberate mental challenge report weaker results); the structural/genomic nature means short trials of 1–2 weeks are insufficient — most community discontinuations likely occurred before the synaptogenic mechanism could manifest.
Community Consensus
Three distinct community populations adopt Dihexa: (1) nootropic optimizers, drawn by the '10 million times more potent than BDNF' framing and the 'Real Limitless pill' cultural narrative (a framing that dramatically outpaces the evidence base — no human RCTs, Notice of Concern on the foundational paper); (2) neurological injury and disease communities — TBI patients, post-concussion recovery, early Alzheimer's or dementia, anoxic brain injury — where the risk-benefit calculus is more favorable given severe baseline impairment and lack of effective alternatives; (3) autoimmune neurological involvement populations (Hashimoto's, lupus) seeking relief from brain fog. The emotional driver behind community adoption is cognitive restoration as quality-of-life repair, not simple productivity enhancement. The dominant community pattern is high theoretical interest combined with low completion rates: trial for weeks to months → uncertain or modest subjective effects → discontinuation when the cancer risk is weighed against unclear benefit. The skin mole growth signal from early adopter reports has not been systematically incorporated into monitoring practice. The FDA Category 2 removal (April 2026) ended regulated compounding pathway but has not significantly changed community sourcing behavior — non-clinical supply remains common. Documented product-identity fraud inflates null-effect reports and undermines community efficacy assessment.
Risks & Monitoring
Gastrointestinal distress (nausea, stomach upset) is the most frequently reported manageable adverse effect; mitigated by taking with food.
Skin mole growth and darkening were reported in Russian early adopter communities — mechanistically plausible via systemic HGF/c-Met angiogenic amplification throughout peripheral tissues expressing HGF (liver, kidney, lung). No systematic Western community monitoring for this signal exists. The primary mechanistic risk is oncogenic: c-Met is a proto-oncogene, and systemic HGF stabilization amplifies HGF/c-Met signaling in all tissues, not only the brain. Gain-of-function c-Met mutations drive papillary renal carcinoma, gastric cancer, and hepatocellular carcinoma; HGF amplification in occult tumor contexts is a plausible tumor-promotion pathway. The magnitude of this risk at community doses in healthy individuals is unknown — no long-term human cohort data exists — but it is mechanistically non-trivial and cannot be dismissed. The dominant community discontinuation pattern is not 'I felt bad effects so I stopped' but 'I'm not sure it's working and the downside risk is irreversible.' No sex hormone suppression has been documented; Dihexa has no androgenic or estrogenic activity. Hard contraindications: active or prior malignancy (all types, given systemic HGF amplification); family history of c-Met-driven cancers; pregnancy or breastfeeding (HGF has roles in placental development); any active angiogenesis-related condition.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
HGF/c-Met amplification has systemic angiogenic effects; community reports of mole darkening and growth require photographic baseline for ongoing comparison; any new, rapidly changing, or darkening lesion warrants immediate discontinuation and dermatologic evaluation
HGF is a hepatotropic growth factor expressed in liver and kidney; baseline hepatic and renal function establishes safety reference before systemic HGF amplification; screen for pre-existing organ compromise
HGF has effects on hematopoietic cells; baseline hematologic reference and screen for pre-existing abnormality before initiating compound
Theoretical oncogenic risk via c-Met amplification; ruling out occult malignancy before initiating sustained HGF amplification is minimum risk management; specific screening per age and risk profile
Primary early-warning signal for oncogenic/angiogenic activation; the Russian early adopter mole reports align mechanistically with HGF systemic effects; ongoing monitoring throughout any cycle
Avoid With
Do not combine Dihexa with the following. Sorted highest-severity first.
Why:c-Met is a proto-oncogene; HGF stabilization amplifies HGF/c-Met throughout the body in all tissues expressing HGF; systemic HGF amplification in a cancer context is a plausible tumor-promotion pathway
What to do:Person-level contraindication, not a drug-drug conflict — the compound should not be used regardless of stack composition; includes any history of c-Met-driven cancers (papillary renal carcinoma, gastric, hepatocellular)
Why:Additive HGF/c-Met pathway activation amplifies both synaptogenic potential and oncogenic risk simultaneously
What to do:No commonly available research chemical acts directly on c-Met; relevant for advanced biohackers combining experimental growth factor peptides
Why:HGF is pro-angiogenic via c-Met; combining with other pro-angiogenic agents potentiates angiogenesis risk in systemic tissues
What to do:Most relevant in biohackers combining multiple experimental growth factor compounds
Protocols By Goal
Cognitive repair in TBI or post-concussion: 25 mg oral daily for 4–8 weeks; pair with NeuroPep for glutamate toxicity (distinct mechanism, non-redundant), Selank for anxiolytic stabilization, Alpha-GPC for cholinergic consolidation; active cognitive engagement required throughout; monitor for GI distress and adjust to food-paired dosing. Age-related or neurodegenerative cognitive decline: 15–25 mg oral daily or every other day; combine with Lion's Mane (NGF pathway, complementary not redundant), Alpha-GPC (cholinergic consolidation); expect long latency (weeks to months); this population has baseline synaptic deficit and the HGF amplification mechanism has more substrate to work on — best evidence-consistent application. General biohacker optimization in healthy individuals: evidence basis is weakest here; if pursued, start at 15 mg oral once weekly; require active cognitive engagement; evaluate after 6 weeks minimum before any dose escalation; the risk-benefit calculus is least favorable in this population. Autoimmune brain fog (Hashimoto's, lupus): similar protocol to TBI recovery; 15–25 mg oral daily; 4–6 week cycle; the HGF anti-inflammatory property at c-Met is the theoretical basis; proceed with awareness that immune-HGF interactions are complex.
Dosing Details
No human RCT dose has been established. All dosing is extrapolated from animal studies and practitioner/community practice.
Two distinct philosophies exist in the community. The first is daily oral dosing: 15 mg (low end), 25 mg (community standard), 45 mg (high end), taken as oral capsules with food to minimize GI distress. The second is once-weekly dosing: 25 mg oral, advocated by practitioners emphasizing that the genomic/structural mechanism does not require daily saturation and a long half-life means less frequent dosing is sufficient. The injectable route is less common: 1–5 mg subcutaneous or intramuscular, reducing required dose relative to oral. Some pre-removal clinic-style protocols used 30 mg oral daily. Cycle length by community consensus: 4–8 weeks, then a break; the cycle-and-break approach is used as a theoretical oncogenic risk management strategy. Some TBI and neurological recovery protocols extend to 12 weeks. Long-term continuous use is not community-endorsed given the oncogenic concern. Timing matters: the compound requires active cognitive engagement (deliberate learning, problem-solving, complex tasks) during administration to yield meaningful synaptogenic benefit. Passive administration without mental challenge has limited utility per practitioner guidance. Cholinergic support (Alpha-GPC) is mechanistically important: acetylcholine provides the 'fuel' that functionally consolidates newly formed synapses — without adequate acetylcholine availability, new synaptic connections cannot be maintained and strengthened.
Stacks & Alternatives
Three-axis neuroplasticity stack: Dihexa for structural synaptogenesis (HGF/c-Met), Semax for BDNF upregulation and neurotrophic support, Selank for anxiolytic mood stabilization. Covers structural formation, trophic maintenance, and cognitive calm simultaneously. Practitioner-endorsed combination; Semax and Selank require nasal or injectable administration.
Triple-pathway neuroplasticity: Dihexa → c-Met → synaptogenesis (structural formation), Lion's Mane → hericenones/erinacines → NGF (trophic maintenance), Alpha-GPC → acetylcholine substrate (neurotransmitter consolidation of new synapses). Each pathway is mechanistically independent and non-overlapping. Oral-only for all three; most accessible evidence-based stack rationale.
TBI recovery protocol covering two distinct downstream injury mechanisms: glutamate toxicity (NeuroPep) and synaptic communication disruption (Dihexa). Alpha-GPC provides cholinergic consolidation of new synapses. Selank provides anxiolytic stabilization during recovery. Most applicable in post-TBI or post-anoxic injury context per practitioner guidance.
Combines synaptic architecture repair (Dihexa) with mitochondrial energy optimization (MOTS-c, SS-31). Rationale: new synapse formation and maintenance are energetically expensive; mitochondrial support may enable full expression of synaptogenic gains. Less community-documented than the neuroplasticity core stacks.
Alternatives
Stack Cost
Specialist tax: Dihexa consumes an experimental CNS-repair lane plus an immune/cancer-risk lane, with zero human trials, c-Met oncogenic uncertainty, skin surveillance, strict cancer-history exclusions, and unusually fragile sourcing.
The article repeatedly frames systemic HGF/c-Met amplification as the central risk: c-Met is a proto-oncogene, active or prior malignancy is a hard contraindication, and no long-term human safety data quantify tumor-promotion risk.
The intended effect is structural synaptogenesis rather than acute neurotransmitter modulation. The article says benefit requires weeks of use plus active cognitive engagement, works best in deficit states, and is least evidence-consistent in healthy optimizers.
recommendedPanels requires baseline mole mapping, ongoing skin checks, age-appropriate cancer screening, CBC, and metabolic function context. These do not prove safety; they are uncertainty-management controls around a mechanism with no human long-term cohort.
practicalitiesSummary and communityExperience identify confirmed product-identity fraud, post-April-2026 narrowed regulated compounding pathway, and HPLC testing as minimum due diligence. A null response may mean no active Dihexa rather than true nonresponse.
stackingConflicts hard-excludes other HGF/c-Met agonists and cautions against pro-angiogenic growth-factor stacking. The more common issue is not ordinary drug metabolism but additive growth-factor and angiogenesis pressure.
- ·Treat Dihexa as the only HGF/c-Met amplification experiment in a stack; do not combine it with other c-Met agonists, HGF-activating compounds, or deliberately pro-angiogenic growth-factor experiments.
- ·Do not allocate this lane to healthy marginal optimization unless the user has explicitly accepted that the article rates benefit weakest in healthy optimizers and cancer downside as unquantifiable.
- ·Do not use it in anyone with active malignancy, prior malignancy, strong c-Met-driven cancer history, unexplained lesions, or active angiogenesis-related disease.
- ·Neurological injury or deficit contexts are the only article-consistent use cases where the risk-benefit calculus may become plausible; even there, caregiver observation and baseline function tracking are required.
- ·Run Dihexa with active cognitive rehabilitation or deliberate learning, not as a passive nootropic; the evidence indicates passive administration has limited utility.
- ·Baseline mole mapping with photos and ongoing skin self-exam or dermatology follow-up for new, rapidly changing, or darkening lesions.
- ·Age-appropriate cancer screening and explicit cancer-history review before first dose.
- ·CBC and BMP or CMP context before use, with organ-function reference points because HGF is expressed systemically.
- ·HPLC or equivalent third-party identity testing because the article documents zero-active-product fraud.
- ·A written stop rule for mole changes, cancer-risk discoveries, unexplained systemic symptoms, or uncertain benefit after an adequate trial.
Dihexa is not beginner-appropriate despite oral dosing. The article combines zero human RCTs, a Notice of Concern on the foundational paper, FDA Category 2 removal, c-Met proto-oncogene risk, and confirmed product-identity fraud.
- ·The user is healthy and pursuing marginal focus, motivation, or study productivity.
- ·The user cannot explain the HGF/c-Met cancer-risk tradeoff in their own words.
- ·The product source is unverified or chosen mainly by price.
- ·The user cannot arrange skin monitoring or age-appropriate cancer screening.
There is no hormonal suppression or withdrawal protocol in the article, so stopping is mechanically simple. The off-ramp is harder than ordinary nootropics because effects may be slow, persistent, and uncertain while the feared downside is not immediately measurable.
- ·Uncertainty about whether a short trial was long enough to reveal benefit.
- ·Difficulty distinguishing counterfeit product from biological nonresponse.
- ·Ongoing dermatology or cancer-risk anxiety after discontinuation.
- ·Loss of perceived cognitive gains in injury or deficit populations.
Do not start with active or prior malignancy; complete age-appropriate screening first; stop immediately and seek oncology or dermatology review for suspicious findings.
Require HPLC or equivalent identity testing before use; do not escalate dose or extend cycles to compensate for an unverified product.
Reserve use for deficit or injury contexts where the evidence indicates the evidence-consistent substrate is stronger; use lighter cognitive alternatives for healthy users.
Pair the cycle with deliberate learning, problem-solving, or rehabilitation and measure the target function over weeks rather than expecting acute stimulant-like effects.
The article treats this as a hard contraindication because Dihexa amplifies HGF/c-Met signaling systemically and c-Met is a proto-oncogene.
Mole growth and darkening are the article's practical early-warning signal for systemic growth-factor or angiogenic activity.
womenConsiderations flags HGF roles in placental development and implantation; human safety data are absent.
The article documents HPLC-confirmed counterfeit supply and says testing is minimum due diligence.
Practical Setup
Product-identity fraud is confirmed and not a fringe risk. Non-clinical supply varies widely in quality; post-FDA Category 2 removal (April 2026), regulated compounding pathway narrowed substantially.
The risk-benefit calculus is heavily population-dependent: for neurologically impaired individuals (TBI, post-concussion, early dementia, severe autoimmune brain fog), the asymmetry may favor use given severe baseline and lack of alternatives — an uncertain long-term oncogenic risk may be acceptable against near-term quality-of-life goals. For healthy biohackers seeking marginal cognitive optimization, the risk-benefit does not clearly favor use — the benefit signal is weakest in this population and the oncogenic risk, while theoretical, is a real and unquantifiable unknown. The '10 million times more potent than BDNF' claim requires explicit correction in any practitioner or peer context: it refers to molar concentration in cell culture, not real-world cognitive effect magnitude; the compound working at picomolar concentrations means you need very little to trigger a cellular response — it does not mean 10 million times the cognitive effect. Active cognitive engagement (deliberate learning, problem-solving, reading, novel tasks) is required alongside the compound for meaningful neuroplasticity benefit. Acetylcholine support via Alpha-GPC is mechanistically important: newly formed synapses require acetylcholine availability to be functionally consolidated and maintained. Monitoring: baseline skin mapping with photographs before use; periodic skin examination throughout any cycle; any new, rapidly changing, or darkening mole warrants immediate discontinuation and dermatologic evaluation. Baseline BMP for hepatic and renal function. No sex hormone monitoring required — Dihexa has no suppressive effect.
Mechanism Deep Dive
Primary mechanism: HGF stabilization. Dihexa binds to and stabilizes hepatocyte growth factor (HGF), preventing its enzymatic degradation.
Stabilized HGF signals more intensely through its receptor, c-Met. This is distinct from direct c-Met agonism — Dihexa amplifies endogenous HGF activity rather than substituting for it. Enhanced c-Met activation triggers the PI3K/AKT signaling pathway, which drives synaptogenesis: the physical formation of new synaptic connections. Because HGF is expressed throughout the body (liver, kidney, lung, and other peripheral tissues in addition to the brain), Dihexa's HGF stabilization operates systemically, not only in the CNS. c-Met is a proto-oncogene; gain-of-function c-Met mutations drive papillary renal carcinoma, gastric cancer, and hepatocellular carcinoma; HGF amplification in occult tumor contexts is a plausible tumor-promotion pathway. Secondary mechanism: AT4 receptor agonism and IRAP inhibition. Dihexa derives from angiotensin IV and retains AT4 receptor binding properties. IRAP (insulin-regulated aminopeptidase) is an angiotensin receptor in the hippocampus and cortex that degrades neuropeptides (oxytocin, vasopressin) at the synapse. IRAP inhibition prolongs the half-life of these neuropeptides, enhancing memory consolidation independently of the HGF/c-Met pathway. BBB permeability advantage: exogenous BDNF (MW ~27 kDa) cannot cross the BBB; GDNF (30 kDa), 7S-NGF variants (14,000 kDa), and most neurotrophins are too large for BBB passage and are rapidly degraded by DPP-4 enzymes. Dihexa's small hexapeptide structure with a lipophilic hexanoic acid modification enables oral bioavailability and CNS penetration — addressing a fundamental pharmacological limitation of direct neurotrophin supplementation. Mechanistic distinction from conventional nootropics: caffeine blocks adenosine receptors, racetams modulate acetylcholine, monoaminergics alter neurotransmitter levels — all operate on existing neurotransmitter systems. Dihexa promotes the physical formation of new synaptic connections, a categorically different mechanism: structural rather than modulatory, genomic rather than acute, architectural rather than functional. This is why users should not expect immediate felt effects and why active cognitive engagement is required to direct the synaptogenic activity toward useful circuits.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Dihexa reversed Alzheimer's-like cognitive deficits in rodents dose-dependently
McCoy et al. (2013) PNAS foundational paper; Notice of Concern issued post-publication; not retracted but scientific confidence reduced; no human replication exists
Independent replication of Dihexa cognitive effects in rodents (Horobets 2021)
Limited independent replication; animal only; does not resolve the Notice of Concern on the foundational paper; represents the sum total of controlled evidence
Dihexa is '10 million times more potent than BDNF' at triggering synaptogenesis
Refers to molar concentration comparison in cell culture — not real-world cognitive effect magnitude; marketing extrapolation of this claim to practical potency is scientifically inaccurate and has driven unrealistic community expectations
Practitioner oral dosing tiers: 15 mg (low), 25 mg (typical), 45 mg (high)
Practitioner-derived from clinical practice; no published case series or RCT; anecdotal basis; represents the most actionable dosing reference available given absence of human trial data
Once-weekly dosing recommended given long half-life and genomic mechanism
Practitioner cites 'one or two studies' for long half-life without specific citation; theoretical rationale from genomic mechanism latency is coherent but unconfirmed in human pharmacokinetics
Clinic-style dosing reports used 30 mg compounded capsules before the April 2026 Category 2 change
Included only as historical field context; not an access route or recommendation.
BDNF cannot cross the blood-brain barrier due to molecular weight (~27 kDa)
Well-established pharmacological principle used to contextualize Dihexa's BBB-permeable design advantage over direct BDNF supplementation; GDNF (30 kDa) and other neurotrophins share this limitation
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.